Boehringer Ingelheim and Tessellate Bio have entered into a partnership worth over €500m to develop oral precision medicines ...

But the legal and regulatory framework is evolving to keep pace. The EU AI Act, GDPR and medical device regulations are ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the European Commission (EC) to treat adults with ulcerative colitis (UC).

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...

Now more than ever we need to remain focused on the real goals of DE&I – and whether we call it that or not, we surely must ...

In many pharma teams, the responsibility for keeping prescribing information (PI) up to date online falls into a grey area. > ...

Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T ...

Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with Merck & Co’s anti-PD-1 therapy ...

Medscape is honored to be the lead sponsor of the upcoming Measuring Patient Engagement Summit, taking place in Boston from ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been recommended by the National ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...